(Q46886092)

26 December 2017

title

Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride (English)

1 reference

26 December 2017

author name string

Michael Linden

series ordinal

1

1 reference

26 December 2017

Tabea Scheel

series ordinal

2

1 reference

26 December 2017

Franz-Xaver Eich

series ordinal

3

1 reference

26 December 2017

language of work or name

English

0 references

publication date

9 January 2006

1 reference

26 December 2017

Journal of Psychopharmacology

published in

1 reference

26 December 2017

volume

20

1 reference

26 December 2017

issue

6

1 reference

26 December 2017

page(s)

815-823

1 reference

26 December 2017

Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Clinical symptomatology and drug compliance in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Switching antipsychotic medications: general recommendations and switching to amisulpride

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Amisulpride: a review of its use in the management of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Conventional antipsychotic medications for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Determinants of medication compliance in schizophrenia: empirical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

A comparison of patients who refuse and consent to neuroleptic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Costs and benefits of two doses of fluphenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Sulpiride and mnemonic function: effects of a dopamine D2 receptor antagonist on working memory, emotional memory and long-term memory in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Patient education in schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Good tolerability equals good results: the patient's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Compliance with antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

21 January 2018

Switching to amisulpride

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Schizophrenic and medical inpatients as informed drug consumers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Response to antipsychotic medication: the doctor's and the consumer's view

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Subjective response to antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881106061154

21 January 2018

Identifiers

DOI

10.1177/0269881106061154

1 reference

26 December 2017

1 reference

26 December 2017